{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:23:31Z","timestamp":1780511011189,"version":"3.54.1"},"reference-count":25,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Large B-cell lymphomas represent the most common non-Hodgkin lymphomas and often present as extranodal masses with advanced stage similar to metastatic tumors. Without proper intraoperative, microscopic, immunophenotypic, and cytogenetic evaluation they may be mistaken for other hematopoietic or even nonhematopoietic tumors. Also, diffuse large B-cell lymphomas often have clinical, morphologic, immunophenotypic, and cytogenetic clinical features that are similar to those of other less common B-cell lymphomas. Furthermore, classification of these neoplasms is continually becoming more refined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To provide a rational, methodic approach to the evaluation of large B-cell lymphomas for community practice pathologists who provide general pathology services.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources.\u2014<\/jats:title>\n                    <jats:p>This review incorporates guidelines detailed in the 2017 update to the World Health Organization's Classification of Tumours of Haematopoietic and Lymphoid Tissues in addition to other recent peer-reviewed publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Many large B-cell neoplasms respond favorably to current treatments, but these cases also require accurate and timely diagnoses. We propose a process following a brief checklist that focuses on diffuse large B-cell lymphoma, the most common entity, and rules out other similar lymphomas in a stepwise fashion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2019-0182-ra","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T16:23:22Z","timestamp":1580228602000},"page":"160-167","source":"Crossref","is-referenced-by-count":18,"title":["A Practical Approach to Diagnosis of B-Cell Lymphomas With Diffuse Large Cell Morphology"],"prefix":"10.5858","volume":"144","author":[{"given":"Joy F.","family":"King","sequence":"first","affiliation":[{"name":"From the Department of Pathology, University of Mississippi Medical Center, Jackson. Dr King is now with the Department of Pathology, Baylor Scott & White Medical Center\/Texas A&M College of Medicine Health Science Center, Temple."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Lam","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University of Mississippi Medical Center, Jackson. Dr King is now with the Department of Pathology, Baylor Scott & White Medical Center\/Texas A&M College of Medicine Health Science Center, Temple."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","reference":[{"issue":"11","key":"2020081300330256100_i1543-2165-144-2-160-b01","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: the Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"issue":"1","key":"2020081300330256100_i1543-2165-144-2-160-b02","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"issue":"20","key":"2020081300330256100_i1543-2165-144-2-160-b03","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"2020081300330256100_i1543-2165-144-2-160-b04","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cca.2014.12.033","article-title":"Leukocyte common antigen (CD45) negative follicular lymphoma, a rare immunophenotypic presentation","volume":"442","author":"Wang","year":"2015","journal-title":"Clin Chim Acta"},{"issue":"3","key":"2020081300330256100_i1543-2165-144-2-160-b05","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1586\/17474086.2015.1007862","article-title":"CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options","volume":"8","author":"Castillo","year":"2015","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"2020081300330256100_i1543-2165-144-2-160-b06","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/bjh.14744","article-title":"Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings","volume":"178","author":"Ott","year":"2017","journal-title":"Br J Haematol"},{"issue":"9","key":"2020081300330256100_i1543-2165-144-2-160-b07","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/0046-8177(95)90090-X","article-title":"Expression of cyclin D1 protein in centrocytic\/mantle cell lymphomas with and without rearrangement of the BCL1\/cyclin D1 gene","volume":"26","author":"Swerdlow","year":"1995","journal-title":"Hum Pathol"},{"issue":"5","key":"2020081300330256100_i1543-2165-144-2-160-b08","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0002-9440(10)65399-0","article-title":"Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization","volume":"154","author":"Li","year":"1999","journal-title":"Am J Pathol"},{"issue":"8","key":"2020081300330256100_i1543-2165-144-2-160-b09","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am J Hematol"},{"issue":"8","key":"2020081300330256100_i1543-2165-144-2-160-b10","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3324\/haematol.12810","article-title":"De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients","volume":"93","author":"Yamaguchi","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"2020081300330256100_i1543-2165-144-2-160-b11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/PAS.0b013e318241f050","article-title":"Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression","volume":"36","author":"Zeng","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2020081300330256100_i1543-2165-144-2-160-b12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2559.2012.04260.x","article-title":"SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma","volume":"61","author":"Hsiao","year":"2012","journal-title":"Histopathology"},{"issue":"6","key":"2020081300330256100_i1543-2165-144-2-160-b13","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1365-2141.2011.08771.x","article-title":"Diagnosis of Burkitt lymphoma using an algorithmic approach\u2013applicable in both resource-poor and resource-rich countries","volume":"154","author":"Naresh","year":"2011","journal-title":"Br J Haematol"},{"issue":"5","key":"2020081300330256100_i1543-2165-144-2-160-b14","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/path.1924","article-title":"Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma","volume":"208","author":"Muris","year":"2006","journal-title":"J Pathol"},{"issue":"2","key":"2020081300330256100_i1543-2165-144-2-160-b15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-0609.2010.01467.x","article-title":"Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP","volume":"85","author":"Yoon","year":"2010","journal-title":"Eur J Haematol"},{"issue":"5","key":"2020081300330256100_i1543-2165-144-2-160-b16","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjh.13085","article-title":"CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia","volume":"167","author":"Slack","year":"2014","journal-title":"Br J Haematol"},{"issue":"14","key":"2020081300330256100_i1543-2165-144-2-160-b17","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","article-title":"CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2020081300330256100_i1543-2165-144-2-160-b18","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2174\/1871520616666160902100506","article-title":"Therapeutic use of brentuximab vedotin in CD30+ hematologic malignancies","volume":"17","author":"Fabbri","year":"2017","journal-title":"Anticancer Agents Med Chem"},{"issue":"6","key":"2020081300330256100_i1543-2165-144-2-160-b19","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/j.1349-7006.2008.00813.x","article-title":"Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders: special references to lymphomas surrounding this newly recognized clinicopathologic disease","volume":"99","author":"Shimoyama","year":"2008","journal-title":"Cancer Sci"},{"issue":"1","key":"2020081300330256100_i1543-2165-144-2-160-b20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"6769","key":"2020081300330256100_i1543-2165-144-2-160-b21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"12","key":"2020081300330256100_i1543-2165-144-2-160-b22","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"issue":"7","key":"2020081300330256100_i1543-2165-144-2-160-b23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11864-017-0483-z","article-title":"Clinical impact of the 2016 Update to the WHO lymphoma classification","volume":"18","author":"Lynch","year":"2017","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"2020081300330256100_i1543-2165-144-2-160-b24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00428-017-2199-7","article-title":"The clinicopathologic spectrum of mature aggressive B cell lymphomas","volume":"471","author":"Rimsza","year":"2017","journal-title":"Virchows Arch"},{"issue":"2","key":"2020081300330256100_i1543-2165-144-2-160-b25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12308-008-0017-5","article-title":"Translocation detection in lymphoma diagnosis by split-signal FISH: a standardised approach","volume":"1","author":"van Rijk","year":"2008","journal-title":"J Hematop"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/2\/160\/2500937\/arpa_2019-0182-ra.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/2\/160\/2500937\/arpa_2019-0182-ra.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:36:46Z","timestamp":1764790606000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/144\/2\/article-p160.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2019-0182-ra","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}